Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Revenue (2016 - 2025)

Guided Therapeutics' Revenue history spans 15 years, with the latest figure at $60000.0 for Q3 2025.

  • For Q3 2025, Revenue changed N/A year-over-year to $60000.0; the TTM value through Sep 2025 reached $178000.0, up 368.42%, while the annual FY2024 figure was $7000.0, 92.86% down from the prior year.
  • Revenue for Q3 2025 was $60000.0 at Guided Therapeutics, down from $117000.0 in the prior quarter.
  • Across five years, Revenue topped out at $117000.0 in Q2 2025 and bottomed at $1000.0 in Q4 2024.
  • The 5-year median for Revenue is $19000.0 (2021), against an average of $28923.1.
  • The largest annual shift saw Revenue skyrocketed 780.0% in 2023 before it tumbled 96.88% in 2024.
  • A 5-year view of Revenue shows it stood at $60000.0 in 2021, then plummeted by 95.0% to $3000.0 in 2022, then surged by 966.67% to $32000.0 in 2023, then crashed by 96.88% to $1000.0 in 2024, then surged by 5900.0% to $60000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Revenue are $60000.0 (Q3 2025), $117000.0 (Q2 2025), and $1000.0 (Q4 2024).